The earnings call reflected a strong positive sentiment with significant achievements in revenue growth, prescription numbers, and financial stability. The momentum of OJEMDA's launch and the promising pipeline developments outweighed the single noted lowlight of discontinuing the VRK1 program.

Company Guidance -

Q3 2025

During the Day One Biopharmaceuticals Q2 2025 Earnings Conference Call, the company reported substantial growth and provided guidance for the fiscal year. OJEMDA, their lead product, achieved $33.6 million in net product revenue for Q2, marking a 10% increase over Q1 and contributing to a trailing 12-month revenue of $113.1 million. The company issued full-year 2025 net revenue guidance of $140 to $150 million, driven by strong demand, prescriber adoption, and payer coverage. The quarter saw over 1,000 prescriptions, with a 15% quarter-over-quarter growth in prescriptions. Day One highlighted a 95% paid patient rate and a 90% initial approval rate for OJEMDA. Additionally, they emphasized the strategic advantage of a strong balance sheet with $453 million in cash and no debt. They are progressing with the FIREFLY-2 trial and are advancing their PTK7-targeted ADC, DAY301, through Phase Ia trial dose escalation.

OJEMDA Surpasses Expectations

OJEMDA generated $113.1 million in cumulative net revenue in 12 months, demonstrating strong commercial momentum and sustained patient demand.

Double-Digit Revenue Growth

For the second quarter, Day One Biopharmaceuticals delivered $33.6 million in net product revenue, up 10% over the first quarter.

Strong Prescription Growth

The company exceeded 1,000 total prescriptions in Q2 for the first time, with a 15% quarter-over-quarter growth in prescriptions.

High Rate of Payer Coverage

Over 95% of patients on OJEMDA are paid patients, with about 90% receiving approval upon initial submission.

Robust Financial Position

Day One Biopharmaceuticals ended Q2 with $453 million in cash and no debt, ensuring flexibility to execute plans.

Promising Pipeline Developments

Advancing PTK7-targeted ADC, DAY301, through Phase Ia trial and the FIREFLY-2 trial for potential indication expansion of OJEMDA.

Day One Biopharmaceuticals (DAWN) Earnings, Revenues Date & History

The upcoming earnings date is based on a company’s previous reporting, and may be updated when the actual date is announced

Daily Earnings Calendar >

DAWN Earnings History

Report Date	Fiscal Quarter	Forecast / EPS	Last Year's EPS	EPS YoY Change	Slides	Play Transcript
Nov 10, 2025	2025 (Q3)	-0.29 / -	0.38	―	―	―
Aug 05, 2025	2025 (Q2)	-0.36 / -0.29	-0.05	-480.00% (-0.24)
May 06, 2025	2025 (Q1)	-0.44 / -0.35	-0.72	51.39% (+0.37)
Feb 25, 2025	2024 (Q4)	-0.36 / -0.63	-0.63	0.00% (0.00)
Oct 30, 2024	2024 (Q3)	-0.32 / 0.38	-0.54	170.37% (+0.92)
Jul 30, 2024	2024 (Q2)	-0.75 / -0.05	-0.61	91.80% (+0.56)		―
May 06, 2024	2024 (Q1)	-0.66 / -0.72	-0.59	-22.03% (-0.13)	―	―
Feb 26, 2024	2023 (Q4)	-0.57 / -0.63	-0.56	-12.50% (-0.07)	―	―
Nov 06, 2023	2023 (Q3)	-0.59 / -0.54	-0.53	-1.89% (-0.01)	―	―
Aug 07, 2023	2023 (Q2)	-0.61 / -0.61	-0.6	-1.67% (-0.01)	―	―

The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.

Beat

Missed

DAWN Earnings-Related Price Changes

Report Date	Price 1 Day Before	Price 1 Day After	Percentage Change
Aug 05, 2025	$6.88	$5.80	-15.70%
May 06, 2025	$6.99	$6.30	-9.87%
Feb 25, 2025	$11.82	$9.87	-16.50%
Oct 30, 2024	$14.47	$14.72	+1.73%

Earnings announcements can affect a stock’s price. This table shows the stock's price the day before and the day after recent earnings reports, including the percentage change.

FAQ

When does Day One Biopharmaceuticals (DAWN) report earnings?

Day One Biopharmaceuticals (DAWN) is schdueled to report earning on Nov 10, 2025, After Close (Confirmed).

What is Day One Biopharmaceuticals (DAWN) earnings time?

Day One Biopharmaceuticals (DAWN) earnings time is at Nov 10, 2025, After Close (Confirmed).

Where can I see when companies are reporting earnings?

You can see which companies are reporting today on our designated earnings calendar.

What companies are reporting earnings today?

You can see a list of the companies which are reporting today on TipRanks earnings calendar.

What is DAWN EPS forecast?

DAWN EPS forecast for the fiscal quarter 2025 (Q3) is -0.29.

Become an Expert with TipRanks Premium

What am I Missing?

Make informed decisions based on Top Analysts' activity

Know what industry insiders are buying

Get actionable alerts from top Wall Street Analysts

Find out before anyone else which stock is going to shoot up

Get powerful stock screeners & detailed portfolio analysis

Subscribe Now See Plans & Pricing